- Home
- NJR vs LEGN Comparison
NJR vs LEGN Comparison
Compare NJR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NJR | LEGN |
|---|---|---|
| Founded | 1922 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NJR | LEGN |
|---|---|---|
| Price | $54.97 | $36.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $53.75 | ★ $61.33 |
| AVG Volume (30 Days) | 494.7K | ★ 2.6M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | ★ $1,351,305,000.00 | N/A |
| Revenue This Year | $11.42 | $42.68 |
| Revenue Next Year | $2.12 | $30.52 |
| P/E Ratio | $16.17 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $43.46 | $16.24 |
| 52 Week High | $58.57 | $45.30 |
Technical Indicators
Market Signals| Indicator | NJR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 65.17 |
| Support Level | $54.66 | $31.84 |
| Resistance Level | $55.21 | $37.50 |
| Average True Range (ATR) | 1.37 | 2.80 |
| MACD | -0.09 | 0.36 |
| Stochastic Oscillator | 42.31 | 88.65 |
Price Performance
Historical ComparisonAbout NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.